Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials. - Wikidata - wikimedia - TriplyDB

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.

http://www.wikidata.org/entity/Q37730010

about

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease Advances in designs for Alzheimer's disease clinical trials.Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease.CSF biomarkers in neurodegenerative diseases.Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).Development and advanced validation of an optimized method for the quantitation of Aβ42 in human cerebrospinal fluid.Biomarkers will revolutionize the way we diagnose and treat Alzheimer's disease.

P2860

Q28259585-4429FD66-2ADA-4557-A1FB-11ED43992121 Q35997824-9584B9EB-8FEF-4456-982B-62EE02F55D52 Q36576472-CA855093-5579-4312-8B22-391A6FB7006A Q37814497-052C38E8-2A8C-4EF4-8FBC-2FA09A63DFDE Q37837903-435E7D1F-6898-4253-A080-02CE669CD53C Q39803583-D3AD8D73-FE97-41F0-8E63-784897011347 Q42218996-B86DE802-D34C-40E7-AA49-7D3FB436D6FF Q53309205-87AD93D8-5409-4A60-8970-46B4EDA7C43B

P2860

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.

http://www.wikidata.org/entity/Q37730010

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.

@en

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.

@nl

type

label

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.

@en

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.

@nl

prefLabel

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.

@en

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.

@nl

P1433

Q37730010-BAE789D2-65C4-46EA-8D0C-5E763FE2F964

P1476

Q37730010-B1DE43A0-732A-4121-B2D0-9BA205DF2402

P2093

Q37730010-8C2F4BE2-38D0-420C-9BCF-4A218B89D5DB

Q37730010-A3242135-76E0-40A9-B609-CB665459DEE6

Q37730010-DB7E8902-0216-4691-A7A0-37B3E326B04A

Q37730010-F90F977A-DD6B-4F93-B716-DB125701CB7A

P2860

Q37730010-007D2400-2F83-4899-AF81-5C6173857F23

Q37730010-11240CFA-0F89-41F0-BF46-E0948D01C394

Q37730010-137E4C67-598C-4035-8694-19057782C9D8

Q37730010-226EC372-9E55-4DB7-8BFB-6D3BF46728D7

Q37730010-22FAA670-3069-4BA2-9F30-CA30218A7975

Q37730010-269D8BF8-DEE1-43DC-905F-9CCDD343662F

Q37730010-2A82AEEB-363B-4204-88FF-C7588A9D8AC0

Q37730010-32742C1B-C7D1-4E0B-8E3F-9558C58D701C

Q37730010-33262AED-9DC4-4549-B623-62074334C54F

Q37730010-4B95314B-8DE7-4A61-936F-A307D1D8FC9C

P304

Q37730010-6441052C-864D-4DEA-B23B-050AD9FD21B0

P31

Q37730010-E8CC334C-B318-488C-9DDC-EED83F5C718B

P356

Q37730010-2352A78B-FE6A-4D30-8A03-8DD43DA1401E

P433

Q37730010-A37F1CCD-469E-4A37-A527-88ACA506BA17

P478

Q37730010-B6718D3A-3D7F-4382-8505-86581C762BE7

P577

Q37730010-F6824824-469D-4EA7-8F22-C91D3B8A14A1

P698

Q37730010-1D0EB313-11AC-449E-AE25-2A05353E7752

P921

Q37730010-67086B46-A6A3-42BD-A8B0-DA690FE17B72

Q37730010-F4DFD43C-440A-4795-8FF7-3B11EB4F95B9

P356

P1433

Biomarkers in Medicine

P1476

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.

@en

P2093

Eric Siemers

http://www.w3.org/2001/XMLSchema#string

Patrick C May

http://www.w3.org/2001/XMLSchema#string

Robert A Dean

http://www.w3.org/2001/XMLSchema#string

Ronald B DeMattos

http://www.w3.org/2001/XMLSchema#string

P2860

O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Amyloid precursor protein trafficking, processing, and function

Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

The role of biomarkers in clinical trials for Alzheimer disease

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease.

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

P304

81-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/BMM.09.85

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20387304

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease